Dasatinib and Quercetin Outperform Navitoclax in a Mouse Model of Intervertebral Disc Degeneration

Key Takeaways

• DQ reduced disc degeneration grades in SM/J mice
• Navitoclax showed no improvement in severe degeneration
• DQ lowered senescence markers p19ARF, p21, and SASP
• Transcriptomics linked DQ effects to JNK and cell‑cycle pathways

Pulse Analysis

Senescent cells accumulate with age, secreting inflammatory factors that degrade tissue integrity. In the spine, this process fuels intervertebral disc degeneration, a leading cause of chronic back pain and disability. Over the past decade, senolytic drugs—originally derived from oncology—have emerged as a strategy to selectively clear these cells, offering a potentially inexpensive, disease‑modifying approach for age‑related disorders.

In the new study, scientists administered either navitoclax or a dasatinib‑quercetin (DQ) cocktail to SM/J mice, a strain genetically predisposed to early disc degeneration. Navitoclax failed to alter severe degeneration or senescence markers, whereas DQ treatment produced markedly lower degeneration scores, reduced expression of p19ARF, p21, and the SASP, and preserved nucleus pulposus cell viability. Transcriptomic profiling revealed that DQ modulated cell‑cycle regulation and JNK signaling, with parallel effects observed in C57BL/6 mice and human disc cell assays, underscoring a conserved mechanism.

These findings have immediate relevance for the burgeoning senolytic market, suggesting that the DQ combination—already inexpensive and widely available—could be repurposed for spinal health. The study also highlights the need for clinical trials focused on musculoskeletal outcomes, as successful translation could reduce reliance on invasive surgeries and long‑term opioid use. Investors and biotech firms may view DQ as a low‑risk, high‑impact candidate for next‑generation anti‑aging therapeutics, accelerating the shift toward preventive, cell‑targeted interventions.